Literature DB >> 33546881

COVID-19-Associated Suspected Myocarditis as the Etiology for Recurrent and Protracted Fever in an Otherwise Healthy Adult.

Ina Volis1, Ido Livneh2, Khetam Hussein3, Ayelet Raz-Pasteur4.   

Abstract

Current reports concerning cardiac involvement in the novel corona virus disease (COVID-19) mostly document acute myocardial injury at presentation. Here, we present a healthy young male, with presumed acute myocarditis, presenting 20 days after initial diagnosis of COVID-19 - and after a clinical, and apparent laboratory, resolution of the original episode. His sole substantial clinical finding upon admission was fever, which was followed by a witnessed elevation in troponin-I.
Copyright © 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Myocardial injury; Myocarditis; SARS-CoV-2; Viral cardiovascular complications

Mesh:

Substances:

Year:  2020        PMID: 33546881      PMCID: PMC7640947          DOI: 10.1016/j.amjms.2020.11.001

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


Introduction

The novel corona virus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originated in China during December 2019, and rapidly became a worldwide pandemic. Evidence of cardiac involvement of SARS-CoV-2 infection is growing as the disease continues to spread. While the incidence of SARS-CoV-2-positive patients presenting with a spectrum of cardiovascular syndromes is in the rise, various mechanisms for the pathophysiology underlying such myocardial injury were postulated.1, 2, 3 Interestingly, hypothesized mechanisms include a direct viral insult to the heart, as well as an indirect myocardial injury secondary to the overwhelming inflammatory response. While such mechanisms are yet to be established, empiric data currently suggest a negative correlation between an elevation of cardiac biomarkers and patients’ prognosis. , , Notably, reports thus far have focused mostly on the immediate and severe cardiac manifestations of SARS-CoV-2 infection, rather than the delayed cardiac complications of the disease.

Case presentation

Here, we present the case of a healthy and physically active 21-year-old male, with unremarkable medical history with the exception of social smoking who presented to the Corona Department with a fever twenty days after first being diagnosed with COVID-19. The patient was initially tested for SARS-CoV-2 based on his complaints of fever, headache, cough and a concomitant mild pleuritic chest pain, all of which had elapsed within 3 days. Following a positive COVID-19 diagnosis, he was monitored in the setting of COVID-19 ambulatory services of the Israeli Health Maintenance Organization. Eight days after his first positive SARS-CoV-2 test, he tested negative twice for SARS-CoV-2 with a 72-hour interval between these tests. All SARS-CoV-2 examinations mentioned in this case were performed using a polymerase chain reaction evaluation of nasopharyngeal and oropharyngeal swabs. One week after his second negative test, he experienced a loss of smell, based on which he was re-tested for SARS-COV-2, and was found positive. Shortly afterwards he also became feverish again, and following three consecutive days with high fevers, he was referred to our hospital. Upon admission he was stable, with vital signs as following: body temperature of 38.5 °C, heart rate of 110 beats per minute (BPM), oxygen saturation of 96% in room air, blood pressure of 130/70 mmHg. In between febrile episodes he remained relatively tachycardic with a basal heart rate of ~90 BPM. Physical examination revealed a slight hepatosplenomegaly, with no other abnormal findings. Initial laboratory at admission showed a normal, yet measurable Troponin-I (Trop-I) (17 ng/L; normal value <34), as well as elevated C-reactive protein (CRP) (3.87 mg/dl; normal value <0.5) and d-Dimer (2463 ng/ml; normal value <500). Electrolytes, creatinine, and blood count were all within the normal range. Repeated blood panels 36 h after admission were significant for high Trop-I (965 ng/L) and elevated hepatocellular transaminases, up to twice the upper limit of the norm (aspartate transaminase was 52 U/L [0-34] and alanine transaminase was 68 U/L [0-55]). Electrocardiograms (ECG), from both his admission and during his hospitalization, did not demonstrate changes consistent with pericarditis and/or myocardial infarction, and the patient did not suffer from any chest discomfort or dyspnea at any time during his stay in our department. Nonspecific findings in his ECGs, inconsistent with criteria of the above diagnoses, included a minimal ST-depressions and T-wave inversions in lead III, and one-millimeter PR depressions on leads II and III. On subsequent ECGs, PR intervals were normalized within 24 h, while T wave inversions remained unchanged (Fig. 1 ).
Figure 1

Electrocardiogram during peak illness and following resolution.

A. An ECG, conducted on the day of peak Trop-I levels, demonstrating sinus tachycardia and minimal ST depressions with T wave inversions on lead III. In addition, ~1 mm PR depressions are evident on leads II and III. B. An ECG, conducted on the day of patient's discharge, demonstrating normalization of PR interval changes denoted in A, while the previously noted T wave inversions have persisted.

Electrocardiogram during peak illness and following resolution. A. An ECG, conducted on the day of peak Trop-I levels, demonstrating sinus tachycardia and minimal ST depressions with T wave inversions on lead III. In addition, ~1 mm PR depressions are evident on leads II and III. B. An ECG, conducted on the day of patient's discharge, demonstrating normalization of PR interval changes denoted in A, while the previously noted T wave inversions have persisted. Other causative viruses of myocarditis were investigated (cytomegalovirus, Epstein-Barr virus, West Nile virus, Coxiella burnetii, Parvovirus B19, Human herpesvirus 6, Toxoplasma, Hepatitis B virus, Hepatitis C virus, and Human immunodeficiency virus), all of which were excluded by serologic tests. Immunoglobulins G (IgG) for SARS-CoV-2 were detected 2 days following his admission. Bacterial blood cultures were all negative. Computed tomography angiography exhibited no evidence of a pulmonary embolism. Likewise, no pulmonary infiltrates, pericardial or pleural effusion, signs of congestion, or enlargement of the heart's chambers were demonstrated. The patient was treated symptomatically, and both Trop-I and CRP have gradually decreased. On the sixth day of hospitalization – concomitantly with Trop-I level dropping to 29 ng/L, and NT-proBNP level of 29.9 pg/mL (normal value <300) – the patient reported a significant clinical improvement, and was no longer febrile for the first time in a nine days. Trop-I was further monitored down to a level <5 ng/L at the ninth day of hospitalization, at which time basal heart-rate decreased to 60 BPM underscoring that his previous heart rate recordings of 90 BPM at rest, indeed reflected a significant relative tachycardia. Interestingly, his heart rate, body temperature, and Trop-I levels, all trended in a synchronized manner during hospitalization, while his CRP level seemed to follow a similar course – with a delay of ~1 day (Fig. 2 ). Taken together, these findings point out that the initial detected Trop-I level, though seemingly within the norm, was in fact an ominous sign. Ten days after the resolution of his symptoms, and with 3 negative tests for SARS-CoV-2, a transthoracic echocardiogram demonstrated a normal left ventricular ejection fraction of 65%, and a normal global contraction with no wall-motion abnormalities.
Figure 2

Trends in heart rate, body temperature, Trop-I, and CRP during hospitalization.

Trop-I and CRP levels were obtained on days 1,3,4,6,7,9, while CRP was obtained also on days 10 and 13. As Trop-I levels lower than 5 ng/L are undetectable, a value of 0 was assigned when the laboratory result was unmeasurable on day 9. Heart rate and temperature were measured daily. Day 1 represents the patient's admission to our hospital, while on day 14 he was discharged.

Trends in heart rate, body temperature, Trop-I, and CRP during hospitalization. Trop-I and CRP levels were obtained on days 1,3,4,6,7,9, while CRP was obtained also on days 10 and 13. As Trop-I levels lower than 5 ng/L are undetectable, a value of 0 was assigned when the laboratory result was unmeasurable on day 9. Heart rate and temperature were measured daily. Day 1 represents the patient's admission to our hospital, while on day 14 he was discharged.

Discussion

Clinical and laboratory findings in this case, support a diagnosis of subclinical acute myocarditis. The timely dynamics of fever, heart rate, Trop-I, and CRP seems to best fit a myocardial injury secondary to an inflammatory response, hypothesized to underlie extrapulmonary manifestations of SARS-COV-2 infection.1, 2, 3 Other reports concerning cardiac manifestations of COVID-19, published thus far, mostly describe moderate to severely ill patients, many of whom had symptoms suggestive of cardiac and respiratory compromise at the time of initial presentation and COVID-19 diagnosis.6, 7, 8, 9, 10 In this case, however, cardiac damage was isolated; developed approximately 3 weeks following the initial diagnosis; and was preceded by a latent, asymptomatic period with laboratory results indicative of a cure. Furthermore, with the exception of fever and tachycardia, no other symptoms suggestive of a cardiac etiology, were present. Given the existence of an asymptomatic period and documented negative SARS-CoV-2 PCR tests, followed by the reappearance of fever and a positive SARS-CoV-2 PCR test, the question of a possible reinfection is inevitable. There are few reports concerning patients tested positive for the second time – after a documented resolution of a SARS-CoV-2 infection by means of a negative PCR test, accompanied also by a clinical resolution of symptoms.11, 12, 13 Conflicting evidence exist concerning the role of the initial immune response in these cases: while the immune response to SARS-CoV-2 and generation of immunoglobulins have been investigated, , their implications during re-exposure remain uncertain. Some studies suggest that such antibodies may play a protective role in face of re-exposure, as presented in a case report of a 69-year-old female patient, and in a controlled experiment in Rhesus Macaques monkeys. On the other hand, reports presenting a significant number of patients have described a second infection, with a prominent clinical presentation and a positive PCR test for SARS-CoV-2 – after resolution of the original episode, by means of both aspects. , Importantly, for most documented cases of such re-infection, the presence (or absence) of an acquired immune response to the primary infection was not evaluated. It is still unclear whether the immune protection following convalescence is, in some cases, insufficient, or whether an infection and resolution do not necessarily result in the acquisition of immunity. It is also uncertain whether negative PCR tests in-between episodes, reflect viral loads below detection threshold as part of a gradual, yet incomplete, recovery (i.e. a false negative), or indeed a complete resolution. Based on the short asymptomatic period, and the presumed myocarditis presenting ~3 weeks following the initial infection, we tend to assume reactivation of a non-resolved viral infection, rather than re-infection, as the etiology in this case. A definite distinction between a false negative PCR test during the asymptomatic period as part of a continuous illness vs re-infection after a true convalescence is yet to be determined. Notably, if re-infection was indeed the underlying cause in the case presented herein, it may represent an unusual case of myocarditis as the main presentation following re-infection which, to our knowledge, has yet to be documented. In conclusion, the case described herein suggests that fever and tachycardia may be the only clues for a COVID-19-related myocarditis, which can present late in the course of the disease, isolated from other organ damage, and despite apparent resolution of the primary viral infection.
  17 in total

1.  Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging.

Authors:  Julian Alexander Luetkens; Alexander Isaak; Sebastian Zimmer; Annkristin Heine; Markus Velten; Georg Daniel Duerr; Jacob Nattermann; Alois Martin Sprinkart; Christoph Boesecke; Gereon Jonas Rieke; Christian Zachoval
Journal:  Circ Cardiovasc Imaging       Date:  2020-05-13       Impact factor: 7.792

2.  COVID-19 and the Heart.

Authors:  Akbarshakh Akhmerov; Eduardo Marbán
Journal:  Circ Res       Date:  2020-04-07       Impact factor: 17.367

3.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.

Authors:  Shaobo Shi; Mu Qin; Bo Shen; Yuli Cai; Tao Liu; Fan Yang; Wei Gong; Xu Liu; Jinjun Liang; Qinyan Zhao; He Huang; Bo Yang; Congxin Huang
Journal:  JAMA Cardiol       Date:  2020-07-01       Impact factor: 14.676

4.  Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Authors:  Marie Gousseff; Pauline Penot; Laure Gallay; Dominique Batisse; Nicolas Benech; Kevin Bouiller; Rocco Collarino; Anne Conrad; Dorsaf Slama; Cédric Joseph; Adrien Lemaignen; François-Xavier Lescure; Bruno Levy; Matthieu Mahevas; Bruno Pozzetto; Nicolas Vignier; Benjamin Wyplosz; Dominique Salmon; Francois Goehringer; Elisabeth Botelho-Nevers
Journal:  J Infect       Date:  2020-06-30       Impact factor: 6.072

5.  SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Authors:  Abishek Chandrashekar; Jinyan Liu; Amanda J Martinot; Katherine McMahan; Noe B Mercado; Lauren Peter; Lisa H Tostanoski; Jingyou Yu; Zoltan Maliga; Michael Nekorchuk; Kathleen Busman-Sahay; Margaret Terry; Linda M Wrijil; Sarah Ducat; David R Martinez; Caroline Atyeo; Stephanie Fischinger; John S Burke; Matthew D Slein; Laurent Pessaint; Alex Van Ry; Jack Greenhouse; Tammy Taylor; Kelvin Blade; Anthony Cook; Brad Finneyfrock; Renita Brown; Elyse Teow; Jason Velasco; Roland Zahn; Frank Wegmann; Peter Abbink; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Xuan He; Catherine Jacob-Dolan; Nicole Kordana; Zhenfeng Li; Michelle A Lifton; Shant H Mahrokhian; Lori F Maxfield; Ramya Nityanandam; Joseph P Nkolola; Aaron G Schmidt; Andrew D Miller; Ralph S Baric; Galit Alter; Peter K Sorger; Jacob D Estes; Hanne Andersen; Mark G Lewis; Dan H Barouch
Journal:  Science       Date:  2020-05-20       Impact factor: 47.728

Review 6.  Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management.

Authors:  Bhurint Siripanthong; Saman Nazarian; Daniele Muser; Rajat Deo; Pasquale Santangeli; Mohammed Y Khanji; Leslie T Cooper; C Anwar A Chahal
Journal:  Heart Rhythm       Date:  2020-05-05       Impact factor: 6.343

7.  New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient.

Authors:  Enrico Bentivegna; Alberto Sentimentale; Michelangelo Luciani; Maria Letizia Speranza; Ludovica Guerritore; Paolo Martelletti
Journal:  J Med Virol       Date:  2020-06-29       Impact factor: 20.693

8.  Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis.

Authors:  Anwar Santoso; Raymond Pranata; Arief Wibowo; Makhyan Jibril Al-Farabi; Ian Huang; Budhi Antariksa
Journal:  Am J Emerg Med       Date:  2020-04-19       Impact factor: 2.469

9.  COVID-19-related myocarditis in a 21-year-old female patient.

Authors:  In-Cheol Kim; Jin Young Kim; Hyun Ah Kim; Seongwook Han
Journal:  Eur Heart J       Date:  2020-05-14       Impact factor: 29.983

10.  Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome.

Authors:  Nicholas S Hendren; Mark H Drazner; Biykem Bozkurt; Leslie T Cooper
Journal:  Circulation       Date:  2020-04-16       Impact factor: 29.690

View more
  4 in total

Review 1.  Self-limiting COVID-19-associated Kikuchi-Fujimoto disease with heart involvement: case-based review.

Authors:  Anna Masiak; Amanda Lass; Jacek Kowalski; Adam Hajduk; Zbigniew Zdrojewski
Journal:  Rheumatol Int       Date:  2022-01-13       Impact factor: 2.631

2.  COVID-19 Infection and Myocarditis: A State-of-the-Art Systematic Review.

Authors:  Vikash Jaiswal; Zouina Sarfraz; Azza Sarfraz; Dattatreya Mukherjee; Nitya Batra; Gazala Hitawala; Sadia Yaqoob; Abhinav Patel; Preeti Agarwala; Muzna Sarfraz; Shehar Bano; Nishwa Azeem; Sidra Naz; Akash Jaiswal; Prachi Sharma; Gaurav Chaudhary
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

Review 3.  The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury.

Authors:  Bhurint Siripanthong; Babken Asatryan; Thomas C Hanff; Salman R Chatha; Mohammed Y Khanji; Fabrizio Ricci; Daniele Muser; Victor A Ferrari; Saman Nazarian; Pasquale Santangeli; Rajat Deo; Leslie T Cooper; Saidi A Mohiddin; C Anwar A Chahal
Journal:  JACC Basic Transl Sci       Date:  2022-02-09

4.  Myocarditis, Pericarditis and Cardiomyopathy After COVID-19 Vaccination.

Authors:  Salvatore Pepe; Ann T Gregory; A Robert Denniss
Journal:  Heart Lung Circ       Date:  2021-07-30       Impact factor: 2.975

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.